Therapy Directory

Pembrolizumab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Pembrolizumab as a study intervention. Browse Pembrolizumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1852

Shown on this page

Current sort

Live official records

Open in full search

Conditions: PTCL, CTCL
Interventions: Pembrolizumab, Pralatrexate, Decitabine; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 90 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Charlottesville, Virginia

Conditions: Neuroblastoma
Interventions: iC9-GD2 T Cells - frozen, iC9-GD2 T Cells - fresh, Cytoxan, Fludara, Keytruda, iC9-GD2 T cells; Genetic · Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2030
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma
Interventions: Azacitidine, Pembrolizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Melanoma, Advanced Melanoma
Interventions: Biopsy, Biospecimen Collection; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Adrenocortical Carcinoma
Interventions: Pembrolizumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 2
States / cities: Ann Arbor, Michigan • New York, New York

Conditions: MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer
Interventions: S095029, pembrolizumab 200 mg (KEYTRUDA ®); Drug
Lead sponsor: Servier Bio-Innovation LLC; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Ocala, Florida • Noblesville, Indiana • Houston, Texas

Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm, POLD1 Gene Mutation, POLE Gene Mutation, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Stage III Breast Cancer AJCC v7, Stage III Ovarian Cancer AJCC v8, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v8, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8
Interventions: Laboratory Biomarker Analysis, Pembrolizumab; Other · Biological
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 2
States / cities: New Brunswick, New Jersey • New York, New York

Conditions: Cutaneous Sarcoma
Interventions: Pembrolizumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Tampa, Florida • Columbus, Ohio • Houston, Texas

Conditions: Recurrent Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Metastatic Head and Neck Cancer, HNSCC
Interventions: Ramucirumab, Pembrolizumab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Lymphoma
Interventions: CMP-001, Pembrolizumab; Drug
Lead sponsor: Umar Farooq; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Metastatic Breast Cancer, Brain Metastases
Interventions: Pembrolizumab; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 19 Years to 90 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 3
States / cities: New York, New York

Conditions: Melanoma Stage Iii, Melanoma Stage Iv, Melanoma, Melanoma (Skin), Cutaneous Melanoma
Interventions: Denosumab, Pembrolizumab, Nivolumab; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Manchester, New Hampshire • Chapel Hill, North Carolina

About this Pembrolizumab clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Pembrolizumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Pembrolizumab.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Pembrolizumab clinical trials

Filter and sort this therapy

Live official records

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN

Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma

Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma

Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma

Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma

CMP-001 for Relapsed and Refractory Lymphoma

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

About this Pembrolizumab clinical trials directory page